

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Canakinumab for the treatment of systemic juvenile idiopathic arthritis

Provisional matrix of consultees and commentators (pre-referral)

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals (canakinumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Children • Action for Sick Children • Action on Pain • Afiya Trust • Arthritic Association • Arthritis & Musculoskeletal Alliance (ARMA) • Arthritis Care • BackCare • Black Health Agency • Children's Society • Child Growth Foundation • Children's Chronic Arthritis Association • Counsel and Care • Equalities National Council • Leonard Cheshire Disability • Muslim Council of Britain • Muslim Health Network • National Children's Bureau • National Parent and Carer Council • National Parent Partnership Network • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • STEPS Charity Worldwide • WellChild 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Actavis UK (azathioprine, sulfasalazine) • Almus Pharmaceuticals (sulfasalazine) • Arrow Generics (azathioprine) • AstraZeneca (chloroquine) • Focus Pharmaceuticals (azathioprine) • Genesis Pharmaceuticals (sulfasalazine) • GlaxoSmithKline (azathioprine) • Goldshield Pharmaceuticals (methotrexate) • Hameln Pharmaceuticals (methotrexate)

National Institute for Health and Clinical Excellence
 Provisional matrix for the proposed technology appraisal of canakinumab for the treatment of systemic juvenile idiopathic arthritis

Appendix C

Consultees	Commentators (no right to submit or appeal)
<p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Surgeons of Great Britain and Ireland • Bone Research Society • British Association for Surgery of the Knee • British Health Professionals in Rheumatology • British Hip Society • British Institute of Musculoskeletal Medicine • British Institute of Radiology • British Orthopaedic Association • British Pain Society • British Society for Paediatric and Adolescent Rheumatology • British Society for Rheumatology • British Society of Rehabilitation Medicine • British Society of Skeletal Radiology • Chartered Society of Physiotherapists • College of Occupational Therapists • Physiotherapy Pain Association • Primary Care Rheumatology Society • Rheumatoid Arthritis Surgical Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and the College of Radiographers • United Kingdom Clinical Pharmacy 	<ul style="list-style-type: none"> • Hospira (methorexate) • Kent Pharmaceuticals (azathioprine, sulfasalazine) • Merck Sharp & Dohme (infliximab) • Metwest Pharmaceuticals (sulfasalazine) • Mylan (azathioprine, sulfasalazine) • Novartis Pharmaceuticals UK (ciclosporine) • Orion Pharma UK (methotrexate) • Pfizer (etanercept, sulfasalazine) • Roche Products (tocilizumab) • Rosemont Pharmaceuticals (sulfasalazine) • Sandoz (azathioprine, methotrexate) • Sanofi (hydroxychloroquine, leflunomide) • Swedish Orphan (anakinra) • Teva UK (azathioprine, methotrexate, sulfasalazine) • Tillomed Laboratories (azathioprine) • Wockhardt UK (methotrexate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Arthritis Research UK • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

National Institute for Health and Clinical Excellence
 Provisional matrix for the proposed technology appraisal of canakinumab for the treatment of systemic juvenile idiopathic arthritis

Consultees	Commentators (no right to submit or appeal)
<p>Association</p> <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS South of Tyne & Wear • Wolverhampton City NHS PCT • Welsh Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.